2019 American Transplant Congress
A Retrospective Observational Analysis of Tacrolimus Metabolism Rate: No Evidence for Impact on Renal Function
*Purpose: A previous publication found that fast metabolisers of tacrolimus had inferior renal function compared to slow metabolisers in a Caucasian population (Thölking et al.,…2019 American Transplant Congress
Impact of Tacrolimus Formulation on Tacrolimus Level Coefficient of Variations
*Purpose: Increased coefficient of variation (CV) of tacrolimus (FK) levels, indicating high intra-patient FK level fluctuations, are associated with increased rejection, development of donor-specific antibodies,…2019 American Transplant Congress
Is Bariatric Surgery Feasible in the Setting of Liver and Kidney Transplants?
Liver Transplant and Hepatobiliary Surgery, The Houston Methodist Hospital, Houston, TX
*Purpose: Bariatric surgery benefits obese patients by promoting weight loss, improving quality of life, and reducing morbidity and mortality rates. There is concern, however, that…2019 American Transplant Congress
Eupatilin Ameliorates Tacrolimus Induced Nephrotoxicity via Inhibiting Apoptosis
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…2019 American Transplant Congress
Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
*Purpose: Tacrolimus (TAC) is part of the immunosuppression scheme of more than 95% of patients after kidney transplantation in Mexico. Low TAC tacrolimus trough levels…2019 American Transplant Congress
In Depth Look at Acute Rejections in LCP-Tacrolimus (LCPT; Envarsus XR) and Immediate-Release Tacrolimus (IR-Tac)-Treated De Novo Kidney Transplant Recipients
*Purpose: A prospective, randomized controlled trial has shown comparable rates of biopsy-proven rejection (BPAR) between LCPT and IR-Tac treated renal transplant recipients. This analysis aims…2019 American Transplant Congress
BK Virus Infection Disparity between Black and Other Races; Do Not Blame the Mycophenolic Acid
*Purpose: Disparities in kidney transplant outcomes between black recipients and others continue to exist. We sought to examine the impact of race and the differential…2019 American Transplant Congress
FK506 Influence Glucose Metabolism by Short Chain Fatty Acid
*Purpose: FK506 is one of the most common immunosuppressant drugs in organ transplantation, which have been demonstrated to cause glucose metabolism disorder and alterd the…2019 American Transplant Congress
Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients
*Purpose: The gut microbiota alters expression of drug-metabolizing enzymes and transporters, and consequently affects therapeutic dose and response of medicines. We aimed to investigate the…2019 American Transplant Congress
Not All Poor Metabolizers Are Clinically Equal: Evaluating Weight-Based Tacrolimus Outcomes in CYP3A Loss of Function Variants
Vidant Medical Center - Transplant Services, Greenville, NC
*Purpose: CYP3A polymorphisms are an important pharmacotherapeutic consideration due to the extensive CYP metabolism of tacrolimus (TAC) and variable expression among different races. The CPIC…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 14
- Next Page »